Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
Epistemonikos ID: 3461b14a52371b1b3a183eeb13b7331faf567086
First added on: Jul 15, 2020